The global HIV drugs market accounted for $30.89 billion in 2019, and is expected to reach $36.49 billion by 2027, registering a CAGR of 3.8% from 2020 to 2027.
𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
Key players in this market have adopted new product launch as the preferred strategy to expand their business. The key players profiled in this report include Boehringer Ingelheim International GmbH, Merck & Co., Inc., GalaxoSmithKline plc. AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Gilead Sciences, Inc., Johnson & Johnson, and Cipla Limited.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/1867
𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘
- North America accounted for 48.40% market share in 2019, and is expected to maintain this trend over the forecast period.
- On the basis of medication class, the multi-class combination drugs segment is anticipated to grow at a CAGR of 4.1% from 2020 to 2027.
- The Asia-Pacific HIV drugs market is estimated to grow at a CAGR of 4.4% during the forecast period.
As per the industry experts, long-term effect of COVID-19 outbreak is expected to be witnessed over the coming years. The outbreak has led to a situation of financial crisis in many countries. Moreover, in regions severely affected by COVID-19, HIV treatment procedures have been reduced to life or limb salvaging cases, owing to new government directives or hospital guidelines. Furthermore, all these factors are anticipated to impact the peripheral artery disease market as well in the future.
𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/1867
Region-wise, the market is divided into North America, Europe, Asia-Pacific, and LAMEA. The North America region accounted for 48.40% of the overall HIV drugs market in 2019, and is expected to maintain this lead over the forecast period. The growth of the HIV drugs market in the region is attributed to the well-established healthcare system, higher diagnosis & treatment rate, government funding for R&D, and increase in adoption of advanced treatment options for the HIV-infected population. However, the Asia-Pacific and LAMEA HIV drugs markets are projected to grow faster, registering a CAGR of 4.4% & 3.6%, respectively, during the analysis period, owing to the prevalence of a large HIV-infected population in these regions, improvement in the healthcare infrastructure, and rise in the diagnosis & treatment rate of HIV. In addition, government initiatives to increase awareness among people have also boosted the HIV drugs market growth.
𝗚𝗲𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝗲𝗱 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/hiv-drugs-market
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
205, Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060